Dallas, TXNCT05892718Now EnrollingIRB Ready

Advanced Solid Tumor Clinical Trial in Dallas, TX

Access cutting-edge advanced solid tumor treatment through this clinical trial at a research site in Dallas. Study-provided care at no cost to qualified participants.

Sponsored by FBD Biologics Limited

Quick Self-Assessment

See if you qualify for this Dallas location

Preparing your pre-screening questions…

Expert Care in Dallas

Access advanced solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumor treatment provided free

Apply for This Dallas Location

Check if you qualify for this advanced solid tumor clinical trial in Dallas, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Dallas

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Dallas site if eligible
  4. 4Begin participation

About This Advanced Solid Tumor Study in Dallas

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Sponsor: FBD Biologics Limited

Who Can Participate

Inclusion Criteria

Able to understand and willing to sign the ICF.
Male and female subjects of ≥18 years of age.
Histologically/cytologically confirmed, locally advanced solid tumor: subjects with histologically or cytologically confirmed advanced solid tumors refractory to standard therapy, or for which no standard treatment exists or non-Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of therapy.
For subjects with advanced solid tumor - must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline.
For subjects with non-Hodgkin lymphoma - must have non-Hodgkin lymphoma that is measurable or assessable for response per Lugano Classification (with 2016 refinement).
Must have ECOG performance status of 0 to 2 at Screening.
Able to provide tumor tissue samples.
Have life expectancy of ≥12 weeks.

Exclusion Criteria

With known history of hypersensitivity to any components of HCB101.
Known active or untreated CNS metastases and/or carcinomatous meningitis.
Have undergone a major surgery or radical radiotherapy or palliative radiotherapy or have used a radioactive drug that is not completed at least 2 weeks prior to the first dose of HCB101.
Clinically significant cardiovascular condition.
Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia.
With known inherited or acquired bleeding disorder or bleeding diathesis. .
Have RBC transfusion within 4 weeks prior to Screening.
With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.
Any investigational or approved systemic cancer therapy.
Active use of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin ≤ 81 mg/QD.
Have used herbal medication within 14 days prior to the first dose of HCB101.
Have received any treatment targeting the CD47 or SIRPα pathway.
Have other malignancies requiring treatment within 2 years prior to the first dose of HCB101.
Participation in another clinical study with an investigational product administered in the last 14 days prior to receiving the first dose of HCB101.
An investigational device used within 28 days prior to the first dose of HCB101.
Positive for hepatitis B, active hepatitis C infections, positive for HIV, or known active or latent tuberculosis.
Known to have a history of alcoholism or drug abuse.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT05892718) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumor Treatment Options in Dallas, TX

If you're searching for advanced solid tumor treatment options in Dallas, TX, this clinical trial (NCT05892718) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Dallas, TX

See all advanced solid tumors clinical trials recruiting in Dallas — not just this study.

Browse Advanced Solid Tumors Trials in Dallas →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Dallas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Dallas, TX